Insulin Aspart

Insulin Aspart

A fast acting insulin analog (marketed by Novo Nordisk as "NovoLog/NovoRapid") is a man-made form of human insulin. A single amino acid has been slightly changed in its molecular structure. This change helps the fast-acting insulin analog absorb quickly into the bloodstream. As a result, it starts working in minutes, which allows you to take insulin and eat right away. Fast-acting insulin analogs are considered to act similar to the way insulin is released in people without diabetes mellitus.

Novolog allows for a flexible dosing schedule, which allows the patient to adjust their insulin according to any changes in their eating habits.

The safety and efficacy of Insulin aspart (NovoLog/NovoRapid) in real life clinical practice was evaluated in the A1chieve study.

It was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. This analogue has increased charge repulsion, which prevents the formation of hexamers, to create a faster acting insulin. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analogue, which was then harvested from a bioreactor.

According to JDRF, insulin aspart was approved for marketing in the United States by the Food and Drug Administration in June 2000.